Presenter: Dr Norlida Binti Suhaimi Moderator:Dr Wan Rohaidah.

Update Pain Management

Presenter : Dr Norlida Binti SuhaimiModerator : Dr Wan Rohaidah

Intravenous Paracetamol

PCA Oxynorm

Bupenorphine patch

Perioperative lignocaine infusion

Outline presentation…

Intravenous Paracetamol

“A Fatal Accident Inquiry in Scotland in 2011 concluded that a young adult died from liver failure due to an overdoseof paracetamol. The Sheriff found ‘there was, at the time of the death, a prevailing culture of assumed familiarity withthe administration of IV paracetamol, a familiarity derived from the common use of oral paracetamol’. The patient,who weighed 35kg, died nine days after receiving paracetamol 1g IV on a sustained and regular basis.”

IV paracetamol was licensed in the UK in 2004 and

is used routinely in anaesthetic practice.

Paracetamol is frequently used for perioperative

analgesia, alone or in combination with an opioid.

Clinical studies have shown that paracetamol has

potent analgesics and reduce opioid consumption.

Introduction…

for the short-term treatment of moderate pain -

especially following surgery

for the short-term treatment of fever

when administration by IV route is clinically justified by

an urgent need to treat pain or hyperthermia and/or

when other routes of administration are not possible.

IV Paracetamol - therapeutic indications…

in patients with hypersensitivity to

paracetamol

in cases of severe hepatocellular

insufficiency.

IV Paracetamol – contraindications…

Precautions for use:

IV Paracetamol should be used with caution in cases of:

hepatocellular insufficiency

severe renal insufficiency (creatinine clearance ≤ 30

mL/min)

chronic alcoholism

chronic malnutrition (low reserves of hepatic

gluthatione)

Paracetamol has essentially no effect on cyclo-

oxygenase in vitro – but it has been classified as a

NSAID because of its moderate analgesic and

antipyretic properties.

The drug is not associated with the increased

incidence of platelet dysfunction, gastritis, and renal

toxicity that are sometimes associated with NSAIDs

IV Paracetamol – clinical pharmacology…

MOA

Unclear

it is thought to exert its analgesic activity by

inhibiting the synthesis of prostaglandins in the CNS

(central acting) and peripherally blocking pain

impulse generation.

In addition, it has been proposed that

acetaminophen has a serotonergic (5-HT)

mechanism and a cannabinoid agonism mechanism,

which may contribute to its analgesic effect.

It has been proposed that its antipyretic actions

are due to :

- inhibition of the hypothalamic heat-

regulating center,

- inhibition of prostaglandin synthesis within

the central nervous system , by inhibition

of COX-3 (a COX – 1 ) variant.

- cannabinoid agonism.

The pharmacokinetics of intravenous

acetaminophen have been described in several

studies, and the serum therapeutic level required

to produce an analgesic effect is 16 mcg/mL in

adults and 10 mcg/mL in children.

Pharmacokinetics and Pharmacodynamics.

IV PCM has a faster onset and results in more predictable pharmacokinetic than oral or rectal PCM formulations

provides onset of pain relief within five to 10 minutes after administration.

Intravenous

1 hour 2 hours

Bloodconcentration

Intramuscular

Suppository

Effervescent tabletEffective

concentration

Tablet

mean IV C max (maximum plasma concentration of drug) was

nearly twice that observed with oral administration and

nearly four times that observed with rectal administration.

The lag time after oral administration is 20-30 min

The lag time after rectal administration often exceeds 1

hour

A major benefit is that IV PCM may be

administered before or during surgery, permitting

the initiation of effective analgesic therapy in the

early phase of the postoperative period.

When patients are able to tolerate oral intake,

they may be switched from IV to oral PCM to

maintain the predictable analgesia established

by the IV route.

Distribution:

The volume of distribution of paracetamol is

approximately 1 L/kg.

Oral bioavailability 80%

Paracetamol is not extensively bound to plasma

proteins (10%)

Following infusion of 1 g paracetamol, significant

concentrations of paracetamol (about 1.5 μg/mL)

were observed in the Cerebro Spinal Fluid as and

from the 20th minute following infusion.

Paracetamol metabolized by the liver mainly to

glucuronide conjugates but also sulphate and cysteine

conjugates

These are actively excreted in the urine, only small

fraction being excreted unchanged.

N- acetyl-p-amino-benzoquinoneimine is a highly toxic

metabolite of paracetamol that produced in small amount

in therapeutic doses.

It is rapidly conjugated with hepatic glutathione to render

it harmless

Following toxic dose – gluthatione is exhausted, NAPQI

accumulates – then free to form covalent bonds with

sulphydryl groups on hepatocytes resulting cell death and

centrilobular hepatic necrosis

Treatment:

- with oral methionine(enhances gluthatione

synthesis) and/or oral or IV acetylcysteine which is

hydrolysed to a precursor of glutathione

IV Paracetamol - Presentation

Composition:

One ml contains 10mg paracetamol

One 50 ml vial contains 500mg paracetamol

One 100 ml vial contains 1000mg

paracetamol

The 100 ml vial or 100 ml bag is restricted to

adults, adolescents and children weighing more

than 33 kg.

The 50 ml vial is adapted to infants, toddlers and

children weighing less than 33 kg.

Recommended dose of IV paracetamol…

IV Paracetamol should be given by infusion over

15 minutes

minimum dose interval should not be less than

four hours (six hours in patients with renal

impairment).

IV Paracetamol : administration…

Once the vacuum seal of the glass vial has been

penetrated, the dose of IV must be administered

within 6 hours.

IV Paracetamol is a single-use vial, and the

unused portion must be discarded.

To prevent the possibility of an air embolism, it is

important to observe the end of the infusion

can also be diluted in a 0.9% sodium chloride

solution or 5% glucose solution

Use the diluted solution within the hour following

its preparation (infusion time included).

NON–WEIGHT-BASED DOSING:

For 1000 mg (10 mg/mL) doses, deliver from the bottle

Use aseptic technique to prepare the vial and IV line

Insert a vented IV set into upright vial; open vent

Hang bottle; adjust flow for 15-minute infusion

Monitor the end of the infusion in order to prevent the possibility of an air embolism

WEIGHT-BASED DOSING:

For extracted doses <1000 mg (10 mg/mL), deliver from separate container

For small-volume pediatric doses up to 60 mL Using aseptic technique, withdraw appropriate dose from vial and into a syringe as above

Administer over 15 minutes using a syringe pump

Since introduction, there have been concerns

about accidental overdose of IV paracetamol due

to errors in drug prescription and administration,

particularly in children, small adults, the elderly,

alcoholics and those with pre-existing

hepatocellular insufficiency.

Reported errors include:

- incorrect dose in adults with high or low body mass index;

- accidental overdose in children associated with use of

100ml- vials;

- 10-fold drug calculation errors;

- confusion between dose volume in millilitres and dose of

drug in milligrams;

- errors when setting up infusion pumps;

- and duplication of doses between the ward and

the operating theatre or recovery.

IV paracetamol should be prescribed carefully,

according to the weight, age and co-morbidities of the

patient. The upper dose limit for each single dose and

in each 24-hour period should not be exceeded.

50ml vials of IV paracetamol should be used for

patients less than 33kg. In infants and small children,

doses should be measured accurately using a syringe.

SALG recommendations…

Enquiry about recent paracetamol ingestion

should form part of routine pre-operative

assessment.

All doses of paracetamol administered in the

operating theatre should be recorded on the drug

administration chart and in the anaesthetic

record.

Advice should be sought from the local poisons information service in all cases of overdose of intravenous paracetamol.

Treatment with acetylcysteine is suggested following a single dose greater than 60mg/kg.

IV paracetamol remains under intensive monitoring by the MHRA.

All suspected adverse reactions to IV paracetamol should be reported to the Yellow Card Scheme and discussed with the local poisons information service.

PCA OxyNorm

Oxycodone is a semi-synthetic derivatives, full

opioid agonist with no antagonist properties.

It has an affinity for kappa, mu and delta opiate

receptors in the brain and spinal cord.

Oxycodone is similar to morphine in its action.

- The therapeutic effect is mainly

analgesic, anxiolytic and sedative.

Oxynorm…

belongs to a group of medicines called strong

analgesics

Indication:

* commonly used as an analgesic in

moderate to severe acute pain

* also used in moderate to severe cancer pain,

and sometimes in chronic non-cancer pain

Reseptor type Location Action when stimulated

µ receptor *brain especially - analgesia

areas involved - physical with sensory & dependence

motor perception - resp depression

and integration - reduced peristalsis

- Abundant in - euphoria

preaqueductal grey. - meiosis

*Spinal cord

δ receptor * brain - Analgesia - anti depressant - physical dependence

Opiod receptor classification…

Ƙ receptor * Brain - Spinal analgesia * Spinal cord - Sedation - Meiosis

NOP receptor * Brain - Anxiety ( nociceptin * spinal cord - DepressionOrphanin FQ - Affect learningPeptide receptor and memory- Most recently - involved in identified tolerance

Reseptor type Location Action whenstimulated

Other pharmacological effects of oxycodone : - respiratory depression, antitussive,

bronchospasm- smooth muscle (constipation, reduction in gastric, biliary and pancreatic secretions, spasm of sphincter of Oddi and transient elevations in serum amylase) - nausea and vomiting : CTZ stimulation via

5- HT3 and dopamine receptors- cardiovascular system (release of histamine and/or peripheral vasodilatation, possibly causing pruritus, flushing, sweating and/or orthostatic hypotension).

Opioids may influence the hypothalamic-pituitary-

adrenal or –gonadal axes.

- Some changes that can be seen include an

increase in serum prolactin, and decreases

in plasma cortisol and testosterone.

Clinical symptoms may be manifest from

these hormonal changes.

Absorption

- 40% to 85% bioavailability after oral

administration

- presence of methoxy group at C3

position of the phenanthrene structure

protects drug against glucuronide

conjugation, and hence first pass effect

-100% bioavailability after iv

administration

Pharmacokinetics…

Distribution:

Distributed to skeletal muscle, liver, intestinal tract,

lungs, spleen and brain.

- tissues with mu, kappa and delta opiod

receptors

Pka 8.5. at pH 7.4, 7.4% unionized

Vd 2-6 L/kg

45% protein binding

Metabolism & Elimination:

Oxycodone has an elimination half-life of approximately 3 hours

metabolised principally in the liver to noroxycodone and

oxymorphone.

Oxymorphone has some analgesic activity but present in plasma

in low concentrations and is not considered to contribute to

oxycodone’s pharmacological effect.

CYP3A4 and CYP2D6 are involved in the formation of

noroxycodone and oxymorphone, respectively.

Metabolites mainly excreted in urine and sweat, accumulates in

patients with renal impairement.

Concentration: Oxycodone hydrochloride 10 mg/ml

Dilute to 1 mg/ml in 0.9% saline, 5% dextrose or

water for injections.

Setting:

* Bolus doses : 0.03 mg/kg (e.g. 1-2mg per 70 kg)

* lock-out time : minimum 5 minutes.

* Background infusion : nil

* Four hour dose limit : 30 mg

PCA oxynorm : administration…

Discontinuation of PCA...

PCA should be discontinued when minimal use is

required and the patient is able to tolerate oral

analgesia

Full explanation and reassurance must be given to the

patient.

Ensure that adequate analgesia is prescribed.

Continue regular pain assessment after the pain

control system has been discontinued and act

accordingly.

Transferring patients between oral and parenteral

oxycodone…

The dose should be based on the following ratio: 2 mg

of oral oxycodone is equivalent to 1 mg of parenteral

oxycodone.

It must be emphasized that this is a guide to the dose

required.

Inter-patient variability requires that each patient is

carefully titrated to the appropriate dose.

Buprenorphine patch

is a semisynthetic, highly lipophilic derivative of the opium

alkaloid thebain

approximately 25-50 times as potent as morphine, usual dose ~

0.3-0.6 mg

Buprenorphine is a partial agonist .has high affinity for, but low

intrinsic activity at, mu receptors.

however, its maximal opioid effects are less than that of full

agonists, and reach a ceiling where higher doses do not result in

increasing effect.

produces analgesia and other effects similar to morphine,

including CVS

BUPRENORPHINE…

peak blood concentration appear at 5 min/i.m., and at 2

hrs/s.l. or oral

plasma protein binding is ~ 96%

plasma half-life is ~ 3 hrs, however, the duration of

action is longer, sometimes up to 6 hrs,

probably due to tissue binding

both N-dealkylation and conjugation occur in the liver,

however most of the drug is excreted unchanged in the

faeces

Transdermal buprenorphine may be used in chronic severe pain

when lower doses of strong opioids are indicated; especially in

patients who need continuous, around-the-clock narcotic pain

relief for an extended period of time.

However, the place of transdermal buprenorphine in pain

management is not well established.

The 7-day patch formulation may have a particular role for

patients who are vomiting or have swallowing difficulties.

Place in therapy…

Transdermal buprenorphine is not suitable for the

management of acute pain because it has a slow

onset and extended duration of action.

transdermal buprenorphine

5 mg (releasing buprenorphine 5

micrograms per hour) every 7 days

10 mg (10 micrograms per hour) every 7

days

20 mg (20 micrograms per hour)every 7 days

Presentation..

Transdermal buprenorphine patches deliver

buprenorphine at a constant rate over 7 days.

The dose equivalence of transdermal

buprenorphine and oral morphine is not

established.

The manufacturer suggests that the dose range

covered by the three patch strengths may be

equivalent to oral morphine up to 90 mg/day.

Other literature and the dose relativities

suggested that the buprenorphine 20-microgram-

per-hour patch might be equivalent to oral

morphine up to 36 mg/day or 53 mg/day

Buprenorphine: a partial agonist

Buprenorphine is a partial agonist so there is a ceiling dose

to its analgesic effect — that is, above a certain dose there

is no further analgesic effect.

The dose at which this occurs in humans is not established

but it is unlikely at the doses in the transdermal patches.

Buprenorphine may trigger opioid withdrawal symptoms in

people who have developed physical dependence on other

opioids.

Buprenorphine has high affinity for mu opioid

receptors and is not easily displaced by opioid

antagonists.

Consequently, the effects of buprenorphine in

overdose are only partially reversed by naloxone

Buprenorphine produces typical opioid adverse

effects (such as constipation, headache, nausea,

vomiting, dizziness).

Local irritation may occur at the application site.

Buprenorphine has a long half-life, so plasma

concentrations fall slowly after the patch is

removed.

Another opioid should not be started within 24 hours of

removing a patch

Safety issues…

Dependence and abuse potential

Physical dependence may develop with chronic use of

buprenorphine.

If a withdrawal syndrome does occur when buprenorphine is

discontinued, it is usually of mild to moderate intensity,

occurs within 2 days and resolves

within 2 weeks.

Avoid prescribing buprenorphine to people who

may be dependent on other opioids because it can

precipitate withdrawal symptoms, including pain.

Transdermal buprenorphine may have lower

abuse

potential than other buprenorphine dosage forms

because of the relatively low plasma

concentrations

achieved, the slow onset of effect and because it

is

likely to be difficult to extract the drug from the

matrix design.

Misuse could take the form of using excessive

amounts of the intact patch or applying it to

sites that would enhance systemic absorption.

It should be used with caution in people with a

past history of dependence on alcohol or other

drugs.

In overdose the effects of buprenorphine are only

partially reversed by naloxone.

The manufacturer states that the dose of naloxone

should start in the usual range but that naloxone 5–12

mg intravenously may be required.

Repeated naloxone doses may be needed because

naloxone has a shorter duration of action than

buprenorphine.

Management of overdose should focus on maintaining

adequate ventilation.

Overdose: effects only partially reversedby naloxone

the effect of buprenorphine on respiratory

depression reaches a ceiling, with higher doses

not increasing respiratory depression to a

significant degree.

However, if buprenorphine is used in combination

with other central nervous system depressants,

such as benzodiazepines, the combined effect on

respiration can be life threatening.

Opioid-naïve patients should start at the lowest

strength.

Supplemental analgesics should be continued as

needed during titration because buprenorphine

concentrations rise slowly.

Patients converting from other opioids (up to the

equivalent of oral morphine 90 mg/day) can also

begin on a low strength of buprenorphine and should

continue with their previous regimen during titration.

Dosing issues…

The dose should be titrated to effect and should not be increased at intervals of less than 3 days.

To increase the dose, remove the current patch and apply a higher strength patch or a combination of 2 patches.

No more than two 20-microgram-per-hour patches should be used at once.

Apply Buprenorphine patch to a hairless or nearly

hairless skin site at the upper outer arm, upper

chest, upper back or the side of the chest.

These 4 sites (each present on both sides of the

body) provide 8 possible application sites.

Rotate Buprenorphine patch among the 8

described skin sites.

Application…

New patches should always be applied to a

different site from the previous one.

Any site should not be re-used for 3–4 weeks to

minimize the risk of local skin irritation

immediately re-using a site can increase the rate

of absorption of buprenorphine.

Discuss the potential adverse effects of

buprenorphine.

Most adverse effects reduce with time.

Constipation may persist; advise patients to drink

adequate amounts of water, increase their fibre

intake and remain as mobile as possible.

Regular laxatives such as lactulose should be

started when buprenorphine is initiated and

continued for long as buprenorphine is used.

PERIOPERATIVE LIGNOCAINE INFUSION

Intravenous infusion of lidocaine decreases

postoperative pain and speeds the return of

bowel function.

tested the hypothesis that perioperative lidocaine

infusion facilitates acute rehabilitation protocol in

patients undergoing laparoscopic colectomy.

Background…

the concept of fast-track surgery has been developed to

reduce postoperative morbidity and duration of

hospitalization, and to accelerate postoperative recovery

and convalescence.

Acute rehabilitation programs combine preoperative

optimization of patients’ physical and psychological status,

attenuation of surgical stress, dynamic pain relief, enforced

mobilization, and early oral (enteral) nutrition, as well as

changes in surgical care de-emphasizing tubes and drains.

Introduction…

Effective postoperative analgesia is key to acute rehabilitation.

An alternative approach to accelerate postoperative recovery

after colon surgery is administration of intravenous

lidocaine, which has analgesic, antihyperalgesic,

and antiinflammatory properties and has been reported

to speed the return of bowel function after surgery.

In a case series, acute rehabilitation after laparoscopic

colectomy

using intravenous lidocaine yielded outcomes similar

to those reported using epidural.

Furthermore,nontoxic plasma lidocaine

concentrations reduce requirements for various

volatile anesthetics in several animal species

although the benefits in humans remain unclear.

intravenous lidocaine is inexpensive, easy to

administer, and relatively safe.

enrolled 45 ASA status I–III patients scheduled to undergo elective

laparoscopic colectomy for nonmalignant disease at

the Centre Hospitalier Universitaire de Lie`ge. (Lie`ge, Belgium)

Patients were enrolled from January 2003 until December 2004.

Exclusion criteria :

- age greater than 70 yr,

- history of gastroduodenal peptic ulcer or renal failure -

hepatic insufficiency,

- psychiatric disorder

- steroid treatment

- chronic treatment with opioid.

Materials and Methods…

Protocol

Patients fasted at least 6 h and were orally

premedicated with 50 mg hydroxyzine and 0.5

mg alprazolam 2 h before surgery.

Lactated Ringer’s solution (8 ml/kg/h) was infused

throughout surgery.

Anesthesia

Patients were randomly allocated to two groups

double blinded study.

Just before induction of anesthesia, patients

assigned to receive lidocaine (n " 22) :

- given an intravenous bolus injection of 1.5 mg/kg

lidocaine followed by a continuous infusion of

2 mg/kg/h.

- The lidocaine infusion was continued at a rate of 1.33

mg/kg/h for 24 h postoperatively.

Patients assigned to the control group (n " 23) were given

equal volumes of saline

General anesthesia was induced with 0.15 ug/kg

sufentanil and 2 mg/kg propofol.

Orotracheal intubation was facilitated with

cis-atracurium,

cis-atracurium was also used for intraoperative

muscle relaxation full muscle relaxation during

surgery

Anesthesia was maintained with sevoflurane in a

mixture of oxygen and air with 2 l/min fresh gas flow.

Sevoflurane concentration was adjusted to maintain

mean arterial pressure within 15% of the preinduction

value.

The use of opioid was restricted during surgery:

Sufentanil, 5 ug, was injected only if mean arterial

pressure increased more than 15% or if heart rate was

greater than 100 beats/min despite the administration

of sevoflurane to an end-tidal concentration of 3.5%.

BIS was monitored

allowed increases in inspired sevoflurane concentration

if BIS exceeded 50.

Core temperature was kept above 36.0°C using a

forced-air warming system.

All patients were given 0.625 mg droperidol and 2 mg

tropisetron, a 5-hydroxytryptamine type 3 antagonist, as

prophylaxis against postoperative nausea and vomiting

1h before the end of surgery.

Surgical Procedure

Two experienced laparoscopic surgeons (B.J.D.,

S.R.L.) performed procedures using a standard four- or five-

trocar technique.

For right colectomy, after intracorporeal dissection of the

ascending colon and the Bauhin valve, the specimen was

exteriorized through a 5- to 6-cm minilaparotomy in the right

lower abdomen.

After resection of the pathologic colon, the anastomosis was

hand-sewn and returned to the abdominal cavity.

The minilaparotomy was then closed.

In laparoscopic sigmoid colectomy, the sigmoid

colon

was first mobilized intracorporeally up to the

rectosigmoid junction.

The rectosigmoid junction was cut using a stapler.

The sigmoid colon was retrieved through a 5- to 6-

cm minilaparotomy in the left lower abdomen and

then resected.

The surgeons were unaware of the patient’s group

assignment.

Postoperative Analgesia

Postoperative analgesia was provided in both groups by

the combination of the paracetamol (acetaminophen)

precursor propacetamol - 2 g propacetamol= 1 g

paracetamol),

2 g intravenously 30 min before the end of surgery and

then every 6 h,

and ketorolac, 30 mg intravenously every 8 h.

Patient-controlled analgesia with piritramide

was used as rescue medication (bolus=1

mg, lockout interval =5 min, no basal infusion).

Twenty-four hours after the end of surgery, the

intravenous infusion of lidocaine or placebo was

stopped

analgesia was provided with oral paracetamol, 1

g every 6 h;

- diclofenac 75 mg twice daily;

- and 100 mg tramadol, if necessary.

An abdominal drain was left in contact with the anastomosis for 24 h.

The bladder catheter was removed on the first postoperative morning. An intravenous infusion of 5% glucose was started after surgery at a rate of 80 ml/h. Patients were allowed to drink water 6 h after surgery. If patients did not report nausea or vomiting, they were given 200

ml of nutritive supplement without residue (Clinutren® 1.5 kcal/ml; Nestle 1 h later.

On the first postoperative day, patients had a light breakfast and lunch. If this food was tolerated, the intravenous infusion was stopped

and a normal diet was resumed. Patients were asked to drink three 200-ml cartons of nutritive

supplement each day.

Acute Rehabilitation…

Active mobilization was started in bed 4 h after

surgery.

Assisted ambulation was enforced on the

subsequent days: 20 m in the morning and 50 m

in the afternoon on postoperative day 1, then 100

m in the morning and the afternoon on day 2.

Defecation and tolerance of normal diet were

required before discharge.

Arterial pressure, heart rate, and end-tidal sevoflurane

concentrations were measured on a Datex-Ohmeda S/5

monitor every 15 min during anesthesia.

BIS scores were also recorded at 15-min intervals.

After surgery, piritramide consumption was recorded every 4

h.

Pain scores were obtained on a visual analog scale at rest,

during mobilization from the supine to the sitting position,

and during coughing at 2 and 6 h postoperatively and at 9:00

AM, 1:00 PM, and 5:00 PM on postoperative days 1 and 2.

Measurements…

Postoperative fatigue scores and gastrointestinal

discomfort (colic, abdominal fullness, internal

discomfort) were also assessed on a visual analog

scale at the same times.

Times to first flatus, defecation, and hospital

discharge were recorded. Episodes of postoperative nausea and vomiting

were noted.

Immediately after induction of anesthesia, the bladder

was catheterized and emptied.

In the first 30 patients (n " 15 in each group), urine was

then collected to measure urinary secretion of cortisol,

epinephrine, and norepinephrine to assess the stress

response during anesthesia and surgery.

Blood samples were drawn in the same patients before

surgery and after surgery at 2, 6, 24, and 48 h.

Plasma concentrations of glucose, C-reactive

protein, cortisol, catecholamines, and leukocyte counts

were measured.

Blood samples were drawn at 5, 15, and 60 min

after anesthetic induction, at the end of surgery,

and 24 h after the end of surgery to measure

plasma lidocaine concentrations

A previous study at same institution using a similar protocol indicated that18 patients per group allowed detecting a 12-h difference

in the recovery of bowel function between the groups, at an alpha level of 0.05 and with 80% power.

therefore enrolled patients until 40 patients (n " 20 in each group) completed the study.

Statistical Analysis

Continuous variables are presented as mean ± SD; they were

compared using analysis of variance for repeated measures for

two criteria (time and treatment)

followed by the Scheffe´ test for multiple comparisons or

the Student t test, as appropriate.

If the Kolmogorov-Smirnov normality test did not demonstrate

gaussian distributions, the Mann–Whitney test was used;

data are then presented as median [25–75% interquartile range].

Categorical data were analyzed with chi-square tests.

P ≤0.05 was considered significant.

Results…

Three patients in the control group, but none in

the lidocaine group, requested tramadol after the

interruption of piritramide patient-controlled

analgesia between the 24th and 48th

postoperative hours:

These patients were given 100, 200, and 400 mg.

patients in the lidocaine group tolerated a normal diet the day

after surgery and had their intravenous infusion interrupted 24

h after surgery,

whereas three patients in the control group required

prolongation of postoperative fasting and intravenous infusion

(31, 54, and 72 h) (P " 0.22).

Four patients in the saline group but only one in the lidocaine

group experienced nausea (P =0.17).

Vomiting occurred in two patients in the saline group and none

in the lidocaine group (P =0.23)

Lidocaine plasma concentrations were measured in 15

patients and were 1.6 ±0.9 ug/ml at 5 min, 1.3 ± 0.4 ug/ml at

15 min, and 1.8 ±0.5 ug/ml at 60 min after the bolus injection

of lidocaine;

2.4 ±0.6 ug/ml at the end of surgery

2.7 ±1.1 ug/ml at the end of the 24-h infusion.

The highest plasma concentrations of lidocaine measured at

each of these time points were 3.5, 2.1, 2.6, 4.0, and 4.6

ug/ml, respectively.

This study demonstrated that perioperative intravenous

infusion of nontoxic doses of lidocaine improved:

- postoperative analgesia,

- reduced postoperative opioid requirements,

- accelerated postoperative recovery of bowel

function,

- attenuated postoperative fatigue,

- reduced the duration of hospitalization,

- facilitated acute rehabilitation

in patients undergoing laparoscopic abdominal surgery.

results further indicated that moderate plasma lidocaine

concentrations reduced sevoflurane requirements necessary for

maintaining intraoperative hemodynamic stability and anesthetic

depth.

Intravenous lidocaine is analgesic,

antihyperalgesic, and antiinflammatory.

These properties are mediated by a variety of

mechanisms, including sodium channel blockade,

as well as inhibition of G protein–coupled

receptors and N-methyl-D-aspartate receptors.

In this study, intravenous lidocaine reduced

postoperative opioid consumption, as well as pain

scores during activity.

the analgesic effect persisted after the lidocaine

infusion was discontinued, which suggests a prevention

of spinal or peripheral hypersensitivity or both.

Inhibition of N-methyl-D-aspartate receptors which play a

major role in postoperative hyperalgesia

Abdominal discomfort was significantly reduced by

lidocaine, which is consistent with the ability of lidocaine

to alleviate visceral pain in animal models.

Systemic lidocaine also improved postoperative bowel

function.

Defecation occurred almost 1 day earlier in the lidocaine

group.

The reduction in ileus duration by intravenous lidocaine

may be mediated by the reduction of postoperative opioid

consumption, the antiinflammatory properties of lidocaine,

and/or a direct inhibition of the sympathetic myenteric

plexus.

In summary, this study demonstrated that perioperative

administration of low doses of intravenous lidocaine

reduces intraoperative anesthetic requirements and has

a clinically relevant beneficial effect on postoperative

recovery after colectomy.

These data suggest that intravenous local anesthetics

can contribute to postoperative acute rehabilitation

programs.

Thank you